SCHEMBL430273

SCHEMBL430273

OCc1cc2ccccc2cc1CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
APOBEC3G Q9HC16 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2A6 P11509 4/20 0.43
CYP1A2 P05177 1/20 0.42
TSHR P16473 2/20 0.41
CYP2D6 P10635 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KCNH2 Q12809 1/20 0.40
ALOX12 P18054 1/20 0.39
TRPM4 Q8TD43 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29583446 1.00 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL901034 0.95 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL3043085 0.95 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL15033126 0.87 ALDH1A1 (0.41) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL1773980 0.85 TRPM4 (0.48) APOBEC3GMEN1KMT2ACYP2A6CYP1A2
SCHEMBL29825149 0.85 TRPM4 (0.48) APOBEC3GMEN1KMT2ACYP2A6CYP1A2
SCHEMBL29768796 0.85 TRPM4 (0.48) APOBEC3GMEN1KMT2ACYP2A6CYP1A2
SCHEMBL1506631 0.83 CYP1A2 (0.39) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL8313745 0.83 MEN1 (0.46) PDE4APDE4BPDE4CPDE4DAPOBEC3G
SCHEMBL647376 0.83 IDO1 (0.45) PDE4APDE4BPDE4CPDE4DAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754221-B2 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-06-17 US claimed
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-09-12 US claimed
EP-1944291-B1 Optically active cyclic alcohol compound and method for producing same MITSUBISHI TANABE PHARMA CORP (JP) 2012-06-13 EP claimed
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-17 US claimed
EP-1944291-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-16 EP claimed
WO-2026100594-A1 POLYCARBONATE RESIN COMPOSITION 三菱エンジニアリングプラスチックス株式会社 2026-05-15 WO disclosed
EP-4674907-A1 RESIN COMPOSITION AND RESIN MOLDED ARTICLE Konica Minolta, Inc. (JP) 2026-01-07 EP disclosed
US-20240392108-A1 RESIN COMPOSITION AND MOLDED ARTICLE MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) 2024-11-28 US disclosed
US-20240329525-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR MANUFACTURING CURED RELIEF PATTERN, AND SEMICONDUCTOR APPARATUS ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-10-03 US disclosed
EP-4397715-A1 RESIN COMPOSITION AND MOLDED ARTICLE Mitsubishi Engineering-Plastics Corporation (JP) 2024-07-10 EP disclosed
US-12031032-B2 Thermoplastic resin including a flame retardant and organopolysiloxane MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) 2024-07-09 US disclosed
US-20240210827-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR MANUFACTURING CURED RELIEF PATTERN, AND SEMICONDUCTOR APPARATUS ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-06-27 US disclosed
EP-1078908-A1 Process for producing dialdehyde Daicel Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
EP-0561948-B1 PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS UPJOHN CO (US) 1995-04-05 EP disclosed
EP-0622373-A1 Phosphonic acid derivatives useful as anti-inflammatory agents THE UPJOHN COMPANY (US) 1994-11-02 EP disclosed
US-5360797-A Bisphosphonic acid derivatives useful as anti-arthritic agents THE UPJOHN COMPANY (US) 1994-11-01 US disclosed
US-5298622-A Spiroindane opiate analogs REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1994-03-29 US disclosed
US-5298498-A Antiarthritic agents THE UPJOHN COMPANY (US) 1994-03-29 US disclosed
EP-0561948-A1 PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS. UPJOHN CO (US) 1993-09-29 EP disclosed
WO-1992010504-A2 PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1992-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME ADH1C, ADH1A, ADH5 PDE4A 2205/4885PDE4B 1890/4885PDE4C 1882/4885
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same ADH1C, ADH1A, ADH5 PDE4A 2205/4885PDE4B 1890/4885PDE4C 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.